Filed on behalf of Patent Owners Genentech, Inc. and City of Hope by:
`
`David L. Cavanaugh
`Reg. No. 36,476
`Heather M. Petruzzi
`Reg. No. 71,270
`Robert J. Gunther, Jr.
`Pro Hac Vice
`Wilmer Cutler Pickering
`Hale and Dorr LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`
`Adam R. Brausa
`Reg. No. 60,287
`Daralyn J. Durie
`Pro Hac Vice
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`Jeffrey P. Kushan
`Reg. No. 43,401
`Peter S. Choi
`Reg. No. 54,033
`Sidley Austin LLP
`1501 K Street, N.W.
`Washington, D.C.
`20005
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`SANOFI-AVENTIS U.S. LLC,
`REGENERON PHARMACEUTICALS, INC., AND,
`GENZYME CORPORATION,
`Petitioners,
`
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owners.
`____________________________________________
`
`Case IPR2015-016241
`Patent 6,331,415
`____________________________________________
`
`PATENT OWNERS’ NOTICE OF FILING OF SUPPLEMENTAL
`EVIDENCE
`
`
`1 Case IPR2016-00460 has been joined with this proceeding.
`
`
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`On May 20, 2016, Petitioners filed and served Petitioners’ Objections to
`
`Evidence Pursuant To 37 C.F.R. § 42.64 in the instant IPR proceeding. See
`
`IPR2015-01624, Paper No. 29. In particular, Petitioners objected to Exhibit 2035
`
`(File History of U.S. Patent No. 4,495,280), as well as paragraphs 161, 189, and
`
`195 of the Expert Declaration of John Fiddes (Ex. 2019) (all of which pertain to
`
`the file history of Exhibit 2035), as lacking completeness under Federal Rule of
`
`Evidence 102. See id. at 1, 3, 9. Patent Owners disagreed with Petitioners’
`
`objections. Furthermore, Petitioners failed to identify any particular pages of the
`
`file history in Exhibit 2035 that are purportedly missing.
`
`In order to obviate these objections, Patent Owners requested and obtained a
`
`copy of the file history of U.S. Patent No. 4,495,280 that has been certified by the
`
`United States Patent and Trademark Office (“USPTO”), and file said certified file
`
`history herewith as Exhibit 2141.
`
`On June 6, 2016, Patent Owners filed a Notice Regarding Supplemental
`
`Evidence (Paper No. 32), in which Patent Owners notified the Board that the time
`
`required to obtain a certified file history from the USPTO can be longer than three
`
`weeks. Patent Owners diligently requested this certified file history upon receiving
`
`Petitioners’ objections, but just recently received the certified file history.
`
`Furthermore, Patent Owners have conferred with Petitioners’ counsel and
`
`they do not object to Patent Owners’ filing of this certified file history after the 10
`
`
`
`1
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`business day deadline for filing of supplemental evidence.
`
`
`
`Respectfully submitted,
`
`/David L. Cavanaugh/
`
`David L. Cavanaugh
`Registration No. 36,476
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`1875 Pennsylvania Avenue, N.W.
`Washington, D.C. 20006
`david.cavanaugh@wilmerhale.com
`Tel.: 202-663-6000
`Fax: 202-663-6363
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: June 30, 2016
`
`
`
`
`2
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Patent Owners’ Updated Exhibit List
`
`Exhibit Name
`
`Expert Report of John Fiddes, Ph.D., Bristol-Myers Squibb
`Company v. Genentech, Inc., No. 2:13-cv-05400-MRP-JEM
`(C.D. Cal.) (Nov. 10, 2014) ("Fiddes Rep.”)
`Declaration of Steven Lanier McKnight Under 37 C.F.R. §
`1.132 in Reexaminations 90/007,542 and 90/007,859 (May 18,
`2007) (“McKnight Decl.”)
`Second Declaration of Steven Lanier McKnight Under 37
`C.F.R. § 1.132 in Reexaminations 90/007,542 and 90/007,859
`(June 3, 2008) (“McKnight Decl. II”)
`Declaration of Dr. Timothy Roy Harris Under 37 C.F.R. §
`1.132 in Reexaminations 90/007,542 and 90/007,859 (Nov. 23,
`2005) (“Harris Decl.”)
`Second Declaration of Dr. Timothy Roy Harris Under 37
`C.F.R. § 1.132 in Reexaminations 90/007,542 and 90/007,859
`(Oct. 26, 2006) (“Harris II Decl.”)
`Declaration of Dr. Douglas A. Rice Under 37 C.F.R. § 1.132 in
`Reexaminations 90/007,542 and 90/007,859 (Oct. 26, 2006)
`(“Rice Decl.”)
`Declaration of Michael Botchan Under 37 C.F.R. § 1.132 in
`Reexaminations 90/007,542 and 90/007,859 (May 20, 2007)
`(“Botchan Decl.”)
`Gilbert, W. & Villa-Komaroff, L., Useful Proteins from
`Recombinant Bacteria, Scientific American, 242:74-94 (1980)
`Expert Report of Dr. E. Fintan Walton, MedImmune, Inc. v.
`Genentech, Inc., No. 03-cv-2567 (C.D. Cal.) (Feb. 29, 2008)
`(“Walton Rep.”)
`Transcript of Deposition of Dr. Jefferson Foote , Bristol-Myers
`Squibb Company v. Genentech, Inc., No. 2:13-cv-05400-
`MRPJEM (Jan. 9, 2015) (“Foote Dep.”)
`Goeddel, D.V., et al., Expression in Escherichia coli of
`chemically synthesized genes for human insulin, Proc. Nat’l
`Acad. Sci. (USA) 76:106-110 (1979) (“Goeddel 1979”)
`Frank, B.H., et al., Two Routes for Producing Human Insulin
`Utilizing Recombinant DNA Technology, Munch. Med. Wschr.,
`125, Suppl. 1:S14-S20 (1983) (“Frank 1983”)
`
`Patent Owners’
`Exhibit Number
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`
`
`3
`
`

`
`Patent Owners’
`Exhibit Number
`2013
`
`2014
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Kohler, G. and Milstein, C., Continuous Cultures of Fused
`Cells Secreting Antibody of Predefined Specificity, Nature
`256:495-497 (Aug. 7, 1975) (“Kohler and Milstein”)
`90/007,542 Office Action Response filed 2/13/2009
`Christie, N.T., et al., Selective amplification of variants of
`complex repeating unit in DNA of a crustacean, Proc. Nat’l
`Acad. Sci., 77(5):2786-2790 (1980) (“Christie 1980”)
`Frommer, et al., Simple repeated sequences in human satellite
`DNA, Nuc. Acids Res. 10(2):547-563 (1982) (“Fromer 1982”)
`Israelewski, N., Structure and function of an AT-rich,
`interspersed repetitive sequence from Chironomus thummi:
`solenoidal DNA, 142 bp palindrome-frame and homologes with
`the sequence for site-specific recombination of bacterial
`transposons, Nuc. Acids Res. 11(20):6985-6996 (1983)
`(“Israelewski 1983”)
`Declaration of Robert J. Gunther Jr. in Support of Motion for
`Admission Pro Hac Vice
`Expert Declaration of John Fiddes, Ph.D., Sanofi-Aventis U.S.
`LLC v. Genentech, Inc., IPR2015-01624 (“Fiddes Decl.”)
`Transcript of Deposition of Dr. Jefferson Foote, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., IPR2015-01624 (Apr. 21, 2016)
`(“Foote Dep.”)
`Expert Declaration of Reiner Gentz, Ph.D., Sanofi-Aventis U.S.
`LLC v. Genentech, Inc., IPR2015-01624 (“Gentz Decl.”)
`Falko G. Falkner & Hans G. Zachau, Expression of Mouse
`Immunoglobulin Genes in Monkey Cells, Nature, 298:286-288
`(1982)
`Expert Report of Sir Gregory Winter, CBE, FRS, Regarding
`Invalidity of U.S. Patent Nos. 6,331,415 and 7,923,221, Eli
`Lilly and Co. v. Genentech, Inc., No. 2:13-cv-07248-MRP-
`JEMx (C.D. Cal.) (Oct. 13, 2014)
`Transcript of Deposition of Sir Gregory Winter, Eli Lilly and
`Co. v. Genentech, Inc., No. 2:13-cv-07248-MRP-JEMx (C.D.
`Cal.) (Jan. 19, 2015) (“Winter Dep.”)
`Keiichi Itakura et al., Expression of Escherichia coli of a
`Chemically Synthesized Gene for the Hormone Somatostatin,
`Science, New Series, 198:1056-1063 (1977)
`
`
`
`4
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Declaration of Arthur Riggs, Cabilly v. Boss, Interference No.
`102,572 (Oct. 28, 1991)
`Declaration of Ronald Wetzel, Cabilly v. Boss, Interference No.
`102,572 (Oct. 28, 1991)
`Declaration of Jeanne Perry, Cabilly v. Boss, Interference No.
`102,572 (Oct. 27, 1991)
`Declaration of William Holmes, Cabilly v. Boss, Interference
`No. 102,572 (Oct. 28, 1991)
`Declaration of Michael Rey, Cabilly v. Boss, Interference No.
`102,572 (Oct. 28, 1991)
`Declaration of Michael Mumford, Cabilly v. Boss, Interference
`No. 102,572 (Oct. 28, 1991)
`Declaration of Shmuel Cabilly, Cabilly v. Boss, Interference
`No. 102,572 (Oct. 28, 1991)
`Declaration of Julie L. Davis, Sanofi-Aventis U.S. LLC v.
`Genentech, Inc., IPR2015-01624 (“Davis Decl.”)
`PROTECTIVE ORDER MATERIAL
`United States Patent and Trademark Office, Patent
`Bibliographic Data (Patent Number: 4,495,280)
`File History of U.S. Patent No. 4,495,280
`U.S. Patent No. 4,351,760
`U.S. Patent No. 4,439,356
`U.S. Patent No. 4,287,300
`U.S. Patent No. 4,174,384
`U.S. Patent No. 4,299,916
`U.S. Patent No. 3,996,345
`U.S. Patent No. 4,199,559
`U.S. Patent No. 4,277,437
`U.S. Patent No. 4,391,904
`U.S. Patent No. 4,374,925
`U.S. Patent No. 4,328,311
`U.S. Patent No. 4,281,061
`U.S. Patent No. 4,366,241
`U.S. Patent No. 4,318,846
`U.S. Patent No. 4,233,402
`U.S. Patent No. 4,261,968
`
`Patent Owners’
`Exhibit Number
`2026
`
`2027
`
`2028
`
`2029
`
`2030
`
`2031
`
`2032
`
`2033
`
`2034
`
`2035
`2036
`2037
`2038
`2039
`2040
`2041
`2042
`2043
`2044
`2045
`2046
`2047
`2048
`2049
`2050
`2051
`
`
`
`5
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`U.S. Patent No. 4,275,149
`U.S. Patent No. 4,272,506
`U.S. Patent No. 4,256,834
`U.S. Patent No. 4,220,722
`U.S. Patent No. 4,235,869
`U.S. Patent No. 4,208,479
`U.S. Patent No. 4,220,450
`U.S. Patent No. 4,193,983
`Reiner Gentz et al., Cloning and Analysis of Strong Promoters
`Is Made Possible By the Downstream Placement of a RNA
`Termination Signal, Proc. Nat’l Acad. Sci. (USA) 78:4936-
`4940 (1981)
`Christie et al., Selective Amplification of Variants of a Complex
`Repeating Unit in DNA of a Crustacean, Proc. Nat’l Acad. Sci.
`(USA) 77(5):2786-2790 (1980)
`Orr-Weaver et al., Multiple, Tandem Plasmid Integration in
`Saccharomyces cerevisiae, Molecular and Cellular Biology
`3:747-49 (1983)
`Takahashi et al., Mechanism of pBR322 Transduction Mediated
`by Cytosine-Substituting T4 Bacteriophage, Mol. Gen. Genet.
`186:497-500 (1982)
`Marrero et al., SP02 Particles Mediating Transduction of a
`Plasmid Containing SP02 Cohesive Ends, J. Bacteriology
`147:1-8 (1981)
`Bastin, Molecular Cloning in Plasmid pBR322 Giving Altered
`Expression of the Tetracycline Resistance Gene, J. General
`Microbiology 123:187-191 (1981)
`Potter et al., On the Mechanism of Genetic Recombination: The
`Maturation of Recombination Intermediates, Proc. Nat’l Acad.
`Sci. (USA) 74:4168-4172 (1977)
`Annie C. Y. Chang and Stanley N. Cohen, Construction and
`Characterization of Amplifiable Multicopy DNA Cloning
`Vehicles Derived from the P15A Cryptic Miniplasmid, J.
`Bacteriology, 134(3): 1141-1156 (1978)
`EP 1 532 260 B1
`
`Patent Owners’
`Exhibit Number
`2052
`2053
`2054
`2055
`2056
`2057
`2058
`2059
`2060
`
`2061
`
`2062
`
`2063
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`
`
`6
`
`

`
`Patent Owners’
`Exhibit Number
`2069
`
`2070
`
`2071
`
`2072
`
`2073
`
`2074
`
`2075
`
`2076
`
`2077
`
`2078
`
`2079
`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`National Library of Medicine, Medical Subject Headings –
`Annotated Alphabetic List (1983)
`Shi-Hsiang Shen, Multiple Joined Genes Prevent Product
`Degradation in Escherichia coli, Proc. Nat’l Acad. Sci. (USA)
`81:4627-4631 (1984)
`Brigitte von Wilcken-Bergmann et al., A Synthetic Operon
`Containing 14 Bovine Pancreatic Trypsin Inhibitor Genes Is
`Expressed in E. coli, EMBO J. 5(12):3219-3225 (1986)
`Expert Report of Carlo M. Croce, M.D., Bristol-Myers Squibb
`Co. v. Genentech, Inc., No. 2:13-cv-05400 (C.D. Cal Nov. 9,
`2014)
`Matthias Wabl and Charles Steinberg, A Theory of Allelic and
`Isotypic Exclusion for Immunoglobulin Genes, Proc. Nat’l
`Acad. Sci. (USA) 79:6976-6978 (1982)
`Wolfgang Kammerer et al., Functional Dissection of
`Escherichia coli Promoters: Information in the Transcribed
`Region Is Involved in Late Steps of the Overall Process, EMBO
`J. 5(11):2995-3000 (1986)
`Ulrich Deuschle et al., Promoters of Escherichia coli: A
`Hierarchy of In Vivo Strength Indicates Alternate Structures,
`EMBO J. 5(11):2987-94 (1986)
`Ulrich Deuschle et al., lac Repressor Blocks Transcribing RNA
`Polymerase and Terminates Transcription, Proc. Natl. Acad.
`Sci. (USA) 83(12):4134-37 (1986)
`Ursula Peschke et al., Efficient Utilization of Escherichia coli
`Transcriptional Signals in Bacillus subtilis, J. Mol. Biol.
`186(3):547-55 (1985)
`Reiner Gentz and Hermann Bujard, Promoters Recognized By
`Escherichia coli RNA Polymerase Selected By Function:
`Highly Efficient Promoters From Bacteriophage T5, J.
`Bacteriol. 164(1):70-77 (1985)
`Hermann Bujard et al., Insertion of Transcriptional Elements
`Outside the Replication Region Can Interfere with Replication,
`Maintenance, and Stability of Co1E1-derived Plasmids, Basic
`Life Sci. 30:45-52 (1985)
`
`
`
`7
`
`

`
`Patent Owners’
`Exhibit Number
`2080
`
`2081
`
`2082
`
`2083
`
`2084
`
`2085
`
`2086
`
`2087
`
`2088
`
`2089
`
`2090
`
`2091
`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Expert Report of John Fiddes, Ph.D., Bristol-Myers Squibb Co.
`v. Genentech, Inc. & City of Hope, 2:13-cv-05400-MRP-JEM
`(C.D. Cal Nov. 10, 2014)
`Bruce Alberts et al., Essential Cell Biology, Chapter 1 (3rd ed.
`2009)
`G. N. Godson et al., Nucleotide Sequence of Bacteriophage G4
`DNA, Nature 276:236-47 (1978)
`Protein Structure, Boundless,
`https://www.boundless.com/biology/textbooks/boundless-
`biology-textbook/biological-macromolecules-3/proteins-
`56/protein-structure-304-11437 (last visited May 12, 2016)
`RCSB Protein Databank, Molecular Machinery: A Tour of the
`Protein Data Bank, Protein Data Bank,
`http://cdn.rcsb.org/pdb101/learn/resources/2014-mol-mach-
`poster.pdf (last visited May 10, 2016)
`Vectors: A Survey of Molecular Cloning Vectors and Their
`Uses, Chapter 1: The Plasmid, pBR322 (Rodriguez, R.L. and
`Denhardt, D.T. eds., 1988)
`Gilbert, Expression of active polypeptides in E. coli, Recomb.
`DNA Tech. Bull. 4(1):4-5 (1981)
`Jürg Meyer and Shigeru Iida, Amplification of
`Chloramphenicol Resistance Transposons Carried by Phage
`P1Cm in Escherichia coli, Molec. Gen. Genet. 176:209-219
`(1979)
`Linscott’s Directory of Immunological and Biological Reagents
`(2d ed. 1982-83)
`Annie Solomon, Bence Jones Proteins and Light Chains of
`Immunoglobulins, Scand. J. Immunol. 5:685-695 (1976)
`Deposition Transcript of James H. Sabry, M.D., Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., No. 2:15-cv-05685 (C.D. Cal)
`(Mar. 16, 2016)
`PROTECTIVE ORDER MATERIAL
`Deposition Transcript of Timothy R. Schwartz, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., No. 15-cv-05685 (C.D. Cal) (Mar.
`1, 2016)
`PROTECTIVE ORDER MATERIAL
`
`
`
`8
`
`

`
`Patent Owners’
`Exhibit Number
`2092
`
`2093
`
`2094
`
`2095
`
`2096
`
`2097
`
`2098
`
`2099
`
`2100
`
`2101
`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Karen Talmadge et al., Eukaryotic Signal Sequence Transports
`Insulin Antigen in Escherichia coli, Proc. Nat’l Acad. Sci.
`(USA) 77:3369-3373 (1980)
`Expert Report of Robert C. Rickert, Ph.D., Bristol-Myers
`Squibb Co. v. Genentech, Inc., No. 2:13-cv-05400-MRP-JEM
`(C.D. Cal. Oct. 13, 2014)
`PROTECTIVE ORDER MATERIAL
`Sanofi, About Us,
`http://www.sanofi.us/l/us/en/layout.jsp?scat=EA904297-0D20-
`4FCA-AAAA-217EC9546F14 (last visited May 6, 2016)
`Sanofi, United States Securities and Exchange Commission
`Form 20-F (for fiscal year ended Dec. 31, 2015), available at
`https://www.sec.gov/Archives/edgar/data/1121404/0001193125
`16493072/d246196d20f.htm
`Sanofi, Sanofi Key Facts and Figures,
`http://en.sanofi.com/our_company/key_facts_and_figures/key_
`facts_and_figures.aspx (last visited May 13, 2016)
`Sanofi, Products,
`http://www.sanofi.us/l/us/en/layout.jsp?scat=8D4FB6C09DD04
`C748C949859D8B2687B (last visited May 9, 2016)
`Regeneron Pharmaceuticals, Inc., United States Securities and
`Exchange Commission Form 10-K (for fiscal year ended Dec.
`31, 2015), available at
`https://www.sec.gov/Archives/edgar/data/872589/00015321761
`6000045/regn-123115x10k.htm
`Regeneron Pharmaceuticals, Inc., Corporate Fact Sheet (Feb.
`2016), available at
`http://files.shareholder.com/downloads/REGN/2034285123x0x
`519844/F1BC3721-4078-424C-94A4-
`640192399E66/REGN_Final_Corporate_Fact_Sheet_1115.pdf
`Certificate of Third Amendment of Amended and Restated
`Certificate of Incorporation (Apr. 16, 2004), available at
`http://www.sec.gov/Archives/edgar/data/318771/00003187710
`4000010/dna-ex3_5.htm
`Genentech, Visit Us, https://www.gene.com/contact-us/visit-us
`(last visited May 9, 2016)
`
`
`
`9
`
`

`
`Patent Owners’
`Exhibit Number
`2102
`
`2103
`
`2104
`
`2105
`
`2106
`
`2107
`
`2108
`
`2109
`
`2110
`2111
`2112
`
`2113
`2114
`
`2115
`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Genentech, “Roche Completes Acquisition of Genentech”
`(Mar. 26, 2009), available at
`http://www.gene.com/media/press-releases/12007/2009-03-
`26/roche-completes-acquisition-of-genentech
`Genentech, About Us, http://www.gene.com/about-us (last
`visited May 9, 2016)
`Genentech, Genentech Fast Facts,
`http://www.gene.com/media/company-information/fast-facts
`(last visited May 9, 2016)
`Genentech, Company Information,
`http://www.gene.com/media/company-information (last visited
`May 9, 2016)
`City of Hope and Affiliates, Consolidated Financial Statements
`(years ended Sept. 30, 2015 and 2014), available at
`http://www.cityofhope.org/doc/1430376104234-
`wcc_031604.pdf
`City of Hope, Locations, http://www.cityofhope.org/about-city-
`of-hope/locations (last visited May 9, 2016)
`City of Hope, Who We Are, http://www.cityofhope.org/about-
`city-of-hope/who-we-are (last visited May 9, 2016)
`City of Hope, About Us, http://www.cityofhope.org/about-city-
`of-hope (last visited May 9, 2016)
`City of Hope, Form 990 (year ending Sept. 30, 2013)
`U.S. Patent No. 4,816,567
`Order Denying Plaintiffs’ Motion for Summary Judgment on
`Double Patenting, Eli Lilly and Co. and ImClone Systems LLC
`v. Genentech, Inc. and City of Hope, Case No. 2:13-cv-07248-
`MRP-JEM (C.D. Cal. Mar. 5, 2015)
`U.S. Patent No. 7,923,221
`Appendix A to Declaration of Julie L. Davis, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., IPR2015-01624
`PROTECTIVE ORDER MATERIAL
`Appendix B to Declaration of Julie L. Davis, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., IPR2015-01624
`PROTECTIVE ORDER MATERIAL
`
`
`
`10
`
`

`
`Patent Owners’
`Exhibit Number
`2116
`
`2117
`
`2118
`
`2119
`
`2120
`
`2121
`
`2122
`
`2123
`
`2124
`
`2125
`
`2126
`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Appendix C to Declaration of Julie L. Davis, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., IPR2015-01624
`PROTECTIVE ORDER MATERIAL
`Appendix D to Declaration of Julie L. Davis, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., IPR2015-01624
`PROTECTIVE ORDER MATERIAL
`Appendix E to Declaration of Julie L. Davis, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., IPR2015-01624
`PROTECTIVE ORDER MATERIAL
`Janssen Biotech, Inc., Our History,
`https://www.janssenbiotech.com/company/history (last visited
`May 9, 2016)
`Johnson & Johnson, United States Securities and Exchange
`Commission Form 10-K (for fiscal year ended Jan. 3, 2016),
`available at
`https://www.sec.gov/Archives/edgar/data/200406/00002004061
`6000071/form10-k20160103.htm
`Sanofi, “Sanofi-aventis to Acquire Genzyme for $74.00 in Cash
`per Share Plus Contingent Value Right” (Feb. 16, 2011),
`available at
`http://en.sanofi.com/Images/28367_20110216_Deal_Genzyme
`_en.pdf
`Maryann P. Feldman et al., Lessons from the
`Commercialization of the Cohen-Boyer Patents: The Stanford
`University Licensing Program, In Intellectual Property
`Management in Health and Agricultural Innovation: A
`Handbook of Best Practices 1797-1807 (A Krattiger et al., eds.,
`2007)
`Ann Gibbons, Molecular Scissors: RNA Enzymes Go
`Commercial, Science, New Series, 251:521 (1991)
`Lita Nelsen, The Rise of Intellectual Property Protection in the
`American University, Science, New Series, 279:1460-61 (1998)
`Frederic M. Scherer, The Size Distribution of Profits from
`Innovation, The Economics and Econometrics of Innovation,
`No. 49/50:495-516 (1998)
`Emily Waltz, Industry Waits for Fallout from Cabilly, Nature
`Biotechnology, 25(7):699-700 (2007)
`
`
`
`11
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Letter from Jay P. Siegel, M.D., FACP, to M. David
`MacFarlane, Ph.D. (Nov. 26, 1997), available at
`http://www.fda.gov/downloads/Drugs/DevelopmentApprovalPr
`ocess/HowDrugsareDevelopedandApproved/ApprovalApplicati
`ons/TherapeuticBiologicApplications/ucm107740.pdf
`Laura Lorenzetti, “7 New Blockbuster Drugs to Watch in
`2016,” Fortune (Mar. 25, 2016), available at
`http://fortune.com/2016/03/25/new-blockbuster-drugs-to-
`watch/
`Ben Hirschler, “Seven $1 Billion-plus Drugs Seen Reaching
`Market in 2016”, Reuters (Feb. 3, 2016), available at
`http://www.reuters.com/article/us-pharmaceuticals-
`blockbusters-idUSKCN0VC0CG
`Cabilly License Agreements
`PROTECTIVE ORDER MATERIAL
`Cabilly Settlement Agreements
`PROTECTIVE ORDER MATERIAL
`Cabilly Royalty Statements
`PROTECTIVE ORDER MATERIAL
`Karen Talmadge et al., Bacteria Mature Preproinsulin to
`Proinsulin, Proc. Nat’l Acad. Sci. (USA) 77:3988-3992 (1980)
`Nancy Lee et al., Cloning with Tandem Gene Systems for High
`Level Gene Expression, Nucleic Acids Res. 12(17):6797-6812
`(1984)
`Transcript of Deposition of Dr. Jefferson D. Foote, Bristol-
`Myers Squibb Co. v. Genentech, Inc. & City of Hope, 2:13-cv-
`05400-MRP-JEM (C.D. Cal Jan. 9, 2015)
`Google Patents, U.S. Patent No. 6,331,415 and List of Patent
`Citations,
`https://www.google.com/patents/US6331415?dq=6331415&hl
`=en&sa=X&ved=0ahUKEwjPhr2C2dTMAhWBVSYKHfVRD
`tIQ6AEIHDAA (last visited May 12, 2016)
`Modified Default Standing Protective Order and Patent
`Owners’ Certification of Agreement to Terms
`Modified Default Standing Protective Order (Redline)
`
`Patent Owners’
`Exhibit Number
`2127
`
`2128
`
`2129
`
`2130
`
`2131
`
`2132
`
`2133
`
`2134
`
`2135
`
`2136
`
`2137
`
`2138
`
`
`
`12
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`Exhibit Name
`
`Exhibit 17 to Deposition Timothy R. Schwartz, Sanofi-Aventis
`U.S. LLC v. Genentech, Inc., No. 2:15-cv-05685 (C.D. Cal)
`(Mar. 1, 2016), Selected Historical Financial Data
`PROTECTIVE ORDER MATERIAL
`Declaration of David F. McGowan in Support of Patent
`Owners’ Motion for Pro Hac Vice Admission
`Certified File History of U.S. Patent No. 4,495,280
`
`Patent Owners’
`Exhibit Number
`2139
`
`2140
`
`2141
`
`
`
`13
`
`

`
`IPR2015-01624
`Patent Owners’ Notice of Filing of Supplemental Evidence
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that, on June 30, 2016, I caused a true and correct copy of
`
`the foregoing materials:
`
` Patent Owners’ Notice of Filing of Supplemental Evidence
`
` Patent Owners’ Updated Exhibit List
`
` Exhibit 2141
`
`
`to be served via electronic mail on the following attorneys of record:
`
`Richard McCormick
`Lisa M. Ferri
`Brian W. Nolan
`Mayer Brown LLP
`1675 Broadway
`New York, NY 10019
`Rmccormick@mayerbrown.com
`LFerri@mayerbrown.com
`BNolan@mayerbrown.com
`MB-Cabilly-IPR@mayerbrown.com
`
`
`
`/Owen K. Allen/
`Owen K. Allen
`Reg. No. 71,118
`Wilmer Cutler Pickering Hale and Dorr LLP
`950 Page Mill Road
`Palo Alto, CA 94304
`
`
`
`1